针对癌症表观基因组的药理学研究。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-06-27 DOI:10.1038/s43018-024-00777-2

Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, Kimberly Stegmaier

{"title":"针对癌症表观基因组的药理学研究。","authors":"Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, Kimberly Stegmaier","doi":"10.1038/s43018-024-00777-2","DOIUrl":null,"url":null,"abstract":"Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including disease initiation, maintenance and therapy resistance. As a result, there have been advances in the development and evaluation of epigenetic therapies for cancer, revealing substantial promise but also challenges. Three epigenetic inhibitor classes are approved in the USA, and many more are currently undergoing clinical investigation. In this Review, we discuss recent developments for each epigenetic drug class and their implications for therapy, as well as highlight new insights into the role of epigenetics in cancer. Stegmaier and colleagues provide a review on the latest development in targeting the cancer epigenome, give an overview of distinct drug classes, and discuss therapeutic possibilities and challenges.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacological targeting of the cancer epigenome\",\"authors\":\"Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, Kimberly Stegmaier\",\"doi\":\"10.1038/s43018-024-00777-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including disease initiation, maintenance and therapy resistance. As a result, there have been advances in the development and evaluation of epigenetic therapies for cancer, revealing substantial promise but also challenges. Three epigenetic inhibitor classes are approved in the USA, and many more are currently undergoing clinical investigation. In this Review, we discuss recent developments for each epigenetic drug class and their implications for therapy, as well as highlight new insights into the role of epigenetics in cancer. Stegmaier and colleagues provide a review on the latest development in targeting the cancer epigenome, give an overview of distinct drug classes, and discuss therapeutic possibilities and challenges.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":23.5000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s43018-024-00777-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-024-00777-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

人们日益认识到表观遗传失调是癌症的标志，包括疾病的诱发、维持和抗药性。因此，癌症表观遗传疗法的开发和评估取得了进展，显示了巨大的前景，但也面临着挑战。美国已批准了三类表观遗传抑制剂，还有更多的表观遗传抑制剂正在进行临床研究。在这篇综述中，我们将讨论每一类表观遗传药物的最新进展及其对治疗的影响，并重点介绍有关表观遗传学在癌症中作用的新见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Pharmacological targeting of the cancer epigenome

查看原文本刊更多论文

Pharmacological targeting of the cancer epigenome

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including disease initiation, maintenance and therapy resistance. As a result, there have been advances in the development and evaluation of epigenetic therapies for cancer, revealing substantial promise but also challenges. Three epigenetic inhibitor classes are approved in the USA, and many more are currently undergoing clinical investigation. In this Review, we discuss recent developments for each epigenetic drug class and their implications for therapy, as well as highlight new insights into the role of epigenetics in cancer. Stegmaier and colleagues provide a review on the latest development in targeting the cancer epigenome, give an overview of distinct drug classes, and discuss therapeutic possibilities and challenges.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.